cobenfy bristol myers squibb

Bristol-Myers Squibb, Alzheimer's and schizophrenia

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.

Business Insider · 2d

Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older

BayStreet · 2d

Bristol Myers Points to New Alzheimer Drug

Bristol Myers Squibb (NYSE:BMY) believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In an interview,

Hosted on MSN · 3d

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.

Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

NBC Connecticut4d

Bristol Myers Squibb CEO describes new drug for treating schizophrenia

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat ...

KOMU1d

FDA approves first new schizophrenia drug in more than 30 years

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

PharmaTimes9d

Cambridge Cognition highlights positive Cantab results

Cambridge Cognition believes these findings highlight Cantab’s effectiveness in measuring cognitive performance improvements.

4don MSN

Bristol sees annual $1.5B in cost savings by end of 2025

Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.

Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors

This was the stock's third consecutive day of losses.

CSR Wire4d

Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year

Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...

AOL8d

This Unpopular Dividend Stock Is a Buy

Bristol-Myers Squibb's recent struggles stem from concerns ... which brought the recently approved schizophrenia treatment Cobenfy to its neuroscience portfolio. Wall Street thinks this next ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results